Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb effects , 2008). Tucidinostat has been applied in clinical trials to Enhance the therapeutic efficacy of R-CHOP therapy, but the potency as well as the molecular system of The mixture of tucidinostat and rituximab keep https://fredg443qbm5.blogsmine.com/profile